Revenue
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Acadia Pharmaceuticals Inc (ACAD)
Price$28.02Cached quote
Net income
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2011
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.07B | $957.8M | $726.4M | $517.2M | $484.1M | $441.8M | $339.1M | $223.8M | $124.9M | $17.3M | $61,000 | $120,000 | $1.1M | $4.9M | $2.1M | $42.1M | $6.4M |
| Gross profit | $982.5M | $876.0M | $684.8M | $507.1M | $473.3M | $431.5M | $327.7M | $211.4M | $115.8M | $14.3M | — | — | — | — | — | — | — |
| Gross margin | 91.69% | 91.46% | 94.27% | 98.03% | 97.76% | 97.69% | 96.65% | 94.47% | 92.73% | 82.23% | — | — | — | — | — | — | — |
| Research & development | $328.8M | $303.2M | $351.6M | $361.6M | $239.4M | $319.1M | $240.4M | $187.2M | $149.2M | $99.3M | $73.9M | $60.6M | $26.7M | $18.8M | $17.3M | $20.6M | $41.6M |
| Operating expenses | $966.7M | $727.0M | $799.8M | $740.8M | $654.6M | $728.3M | $585.6M | $471.3M | $417.3M | $290.1M | $164.7M | $93.3M | $39.4M | $25.8M | $24.9M | $27.0M | $51.9M |
| Operating income | $104.8M | $230.8M | −$73.4M | −$223.6M | −$170.4M | −$286.6M | −$246.5M | −$247.4M | −$292.4M | −$272.8M | −$164.6M | −$93.2M | −$38.3M | −$20.9M | −$22.9M | $15.1M | −$45.5M |
| Operating margin | 9.78% | 24.10% | −10.10% | −43.23% | −35.20% | −64.87% | −72.71% | −110.56% | −234.11% | −1,574.14% | −269,855.74% | −77,691.67% | −3,344.72% | −425.64% | −1,105.56% | 35.82% | −710.55% |
| EBITDA | $116.6M | $246.7M | −$67.8M | −$221.6M | −$167.1M | −$283.7M | −$243.8M | −$244.4M | −$289.7M | −$271.0M | −$164.0M | −$93.0M | −$38.2M | −$20.8M | −$22.6M | $15.7M | −$44.4M |
| EBITDA margin | 10.88% | 25.75% | −9.34% | −42.84% | −34.51% | −64.21% | −71.90% | −109.22% | −231.94% | −1,563.60% | −268,795.08% | −77,520.00% | −3,337.82% | −423.42% | −1,091.78% | 37.26% | −693.19% |
| Net income | $391.0M | $226.5M | −$61.3M | −$216.0M | −$167.9M | −$281.6M | −$235.3M | −$245.2M | −$289.4M | −$271.4M | −$164.4M | −$92.5M | −$37.9M | −$20.8M | −$22.8M | $15.1M | −$45.1M |
| Net profit margin | 36.49% | 23.64% | −8.44% | −41.76% | −34.67% | −63.74% | −69.38% | −109.56% | −231.71% | −1,565.94% | −269,578.69% | −77,062.50% | −3,314.24% | −424.88% | −1,101.35% | 35.93% | −705.50% |
| Basic EPSper basic share | $2.32 | $1.37 | -$0.37 | -$1.34 | -$1.05 | -$1.79 | -$1.60 | -$1.94 | -$2.36 | -$2.34 | -$1.63 | -$0.95 | -$0.44 | -$0.38 | -$0.44 | $0.39 | -$1.20 |
| Diluted EPSper diluted share | $2.30 | $1.36 | -$0.37 | -$1.34 | -$1.05 | -$1.79 | -$1.60 | -$1.94 | -$2.36 | -$2.34 | -$1.63 | -$0.95 | -$0.44 | -$0.38 | -$0.44 | $0.39 | -$1.20 |
Owners
Reported shareholders
24.93%of listed shares
BAKER BROS. ADVISORS LP42.91M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BAKER BROS. ADVISORS LP | 24.93%42.91M shares |
BlackRock, Inc. | 13.08%22.52M shares |
STATE STREET CORP | 5.27%9.08M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 5.13%8.84M shares |
RTW INVESTMENTS, LP | 4.15%7.14M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.35%5.76M shares |
DIMENSIONAL FUND ADVISORS LP | 2.15%3.69M shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.95%3.36M shares |
Palo Alto Investors LP | 1.66%2.86M shares |
GOLDMAN SACHS GROUP INC | 1.50%2.58M shares |
Qube Research & Technologies Ltd | 1.42%2.45M shares |
Point72 Asset Management, L.P. | 1.41%2.43M shares |
CITADEL ADVISORS LLC | 1.27%2.18M shares |
Pictet Asset Management Holding SA | 1.15%1.98M shares |
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.14%1.97M shares |
MARSHALL WACE, LLP | 1.03%1.76M shares |
D. E. Shaw & Co., Inc. | 0.99%1.7M shares |
BRAIDWELL LP | 0.96%1.65M shares |
NORGES BANK | 0.94%1.62M shares |
Frazier Life Sciences Management, L.P. | 0.84%1.44M shares |
Percentages use 172.13M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 26, 2026Form 4 · 10b5-1 | Kihara JamesPRINCIPAL ACCOUNTING OFFICER | SellCommon Stock | 11.4K | $26.08 | $297.9K | 13.1K |
| May 26, 2026Form 4 | Kihara JamesPRINCIPAL ACCOUNTING OFFICER | SellCommon Stock | 5.4K | $21.18 | $114.4K | 24.5K |
| May 4, 2026Form 4 | Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER | SellCommon Stock | 3.5K | $21.79 | $76.4K | 66.1K |
| May 4, 2026Form 4 | Kihara JamesPRINCIPAL ACCOUNTING OFFICER | SellCommon Stock | 1.3K | $21.79 | $29.0K | 29.1K |
| Apr 7, 2026Form 4 | Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER | SellCommon Stock | 2.7K | $22.20 | $60.1K | 62.8K |